Literature DB >> 29321219

What can the lived experience of participating in risky HIV cure-related studies establish?

Nir Eyal.   

Abstract

This response to Gail Henderson et al argues that they were right that interviewees' appraisals of cure study participation should inform (future) protocol review decisions, but wrong to take these appraisals at face value. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Autonomy; Clinical Trials; Decision-making; Ethics; Research Ethics

Mesh：

Year:  2018        PMID： 29321219      PMCID： PMC6093613          DOI： 10.1136/medethics-2017-104593

Source DB:  PubMed          Journal:  J Med Ethics        ISSN： 0306-6800            Impact factor:   2.903


  6 in total

1.  The role of adaptation to disability and disease in health state valuation: a preliminary normative analysis.

Authors:  Paul Menzel; Paul Dolan; Jeff Richardson; Jan Abel Olsen
Journal:  Soc Sci Med       Date:  2002-12       Impact factor: 4.634

2.  Why high-risk, non-expected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies.

Authors:  Lara Buchak
Journal:  J Med Ethics       Date:  2016-06-30       Impact factor: 2.903

3.  Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.

Authors:  Gail E Henderson; Holly L Peay; Eugene Kroon; Rosemary Jean Cadigan; Karen Meagher; Thidarat Jupimai; Adam Gilbertson; Jill Fisher; Nuchanart Q Ormsby; Nitiya Chomchey; Nittaya Phanuphak; Jintanat Ananworanich; Stuart Rennie
Journal:  J Med Ethics       Date:  2017-11-10       Impact factor: 2.903

4.  How to keep high-risk studies ethical: classifying candidate solutions.

Authors:  Nir Eyal
Journal:  J Med Ethics       Date:  2016-06-09       Impact factor: 2.903

5.  The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction.

Authors:  Nir Eyal
Journal:  J Med Ethics       Date:  2016-05-23       Impact factor: 2.903

6.  Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations.

Authors:  Samual A Garner; Stuart Rennie; Jintanat Ananworanich; Karine Dube; David M Margolis; Jeremy Sugarman; Randall Tressler; Adam Gilbertson; Liza Dawson
Journal:  J Virus Erad       Date:  2017-04-01
  6 in total
  7 in total

1.  The Role of Inclusion Benefits in Ethics Committee Assessment of Research Studies.

Authors:  Stuart Rennie; Suzanne Day; Allison Mathews; Adam Gilbertson; Winfred K Luseno; Joseph D Tucker; Gail E Henderson
Journal:  Ethics Hum Res       Date:  2019-05

2.  Bystanders, risks, and consent.

Authors:  Helen Frowe
Journal:  Bioethics       Date:  2019-10-25       Impact factor: 1.898

3.  Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption?

Authors:  Nir Eyal; Monica Magalhaes
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

4.  Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium.

Authors:  Nir Eyal; Steven G Deeks
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

5.  What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study.

Authors:  Marion Fiorentino; Christel Protière; Luis Sagaon-Teyssier; Mohamed Mimi; Lisa Fressard; Michael P Arnold; Olivier Lambotte; Janine Barbot; Sylvie Fainzang; Laurence Meyer; Cécile Goujard; Marie Préau; Bruno Spire; Marie Suzan-Monti
Journal:  J Virus Erad       Date:  2019-09-18

6.  HIV Cure Research: Risks Patients Expressed Willingness to Accept.

Authors:  Allison Kratka; Peter A Ubel; Karen Scherr; Benjamin Murray; Nir Eyal; Christine Kirby; Madelaine N Katz; Lisa Holtzman; Kathryn Pollak; Kenneth Freedburg; Jennifer Blumenthal-Barby
Journal:  Ethics Hum Res       Date:  2019-11

Review 7.  Ethical issues in HIV remission trials.

Authors:  Nir Eyal; Lisa G Holtzman; Steven G Deeks
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.